Abbott Labs (ABT) Stock Falling Ahead of Q2 Earnings Report
NEW YORK (TheStreet) -- Shares of Abbott Laboratories (ABT) - Get Report are falling 0.82% to $41.74 this afternoon as the company prepares to report its 2016 second quarter earnings on Wednesday, July 20 before the market opens.
Analysts surveyed by Thomson Reuters are anticipating earnings of 53 cents per share on $5.24 billion in revenue for the Abbott Park, IL-based healthcare company.
For the second quarter of 2015, Abbott Labs reported earnings of 52 cents on revenue of $5.2 billion.
The company is currently working on two separate deals, one to acquire healthcare diagnostics company Alere (ALR) for $8.4 billion and another to acquire cardiovascular medical device company St. Jude Medical (STJ) for $25 billion.
Abbott Labs recently received FDA approval for an absorbable stent, which dissolves in a patient's body a fear years following procedures.
Separately, TheStreet Ratings rated this stock as a "hold" with a ratings score of C+.
The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins.
However, as a counter to these strengths, TheStreet Ratings finds weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself.
You can view the full analysis from the report here: ABT
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.